nintedanib (Inflammasome therapeutics/Boehringer Ingelheim)

N/A

Report date: 2025/10/27 17:55:13

Base Information

Drug Namenintedanib (Inflammasome therapeutics/Boehringer Ingelheim)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor receptor antagonists

TargetsVascular endothelial growth factor receptor

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsMacular Degeneration

Inactive IndicationsN/A

ATC CodeN/A